Protocols on ImmuneRegen's Homspera(TM) Submitted to RFI, 'Therapeutic
Countermeasures against CDC Category A and B Threat Agents'
SCOTTSDALE, Ariz., Aug. 23 /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, Inc. a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO.OB), announced today that it has recently responded to a Request for Information (RFI) from the Defense Threat Reduction Agency (DTRA) of the Department of Defense for Therapeutic Countermeasures against CDC Category A and B Threat Agents. ImmuneRegen made its submission August 20, 2007 with information on its potential treatment, Homspera(TM).
ImmuneRegen filed a formal response to the RFI respective to its compound Homspera(TM), currently in development as a therapeutic and prophylactic countermeasure against multiple pathogens including multiple biological, chemical and radiological threats. For the purposes of this request, the RFI submission focuses primarily on anthrax countermeasures.
"We believe that Homspera is at the forefront of the development of Category A and B countermeasures," commented Michael Wilhelm, co-founder and CEO of ImmuneRegen. "Our studies have shown Homspera to be effective in protecting experimental animals against the lethal effects of ionizing radiation, infection with anthrax spores, infection with influenza virus, and to be an adjuvant in influenza vaccine studies. We believe Homspera's mode of action includes an immunostimulatory activity that results in enhanced host defenses against multiple pathogens."
Should this RFI lead to further studies, ImmuneRegen expects to partner with appropriate governmental agencies, such as USAMRIID (U.S. Army Medical Research Institute for Infectious Diseases) or AFIP (Armed Forces Institute of Pathology).
Homspera is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera(TM), as Viprovex(R) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.
About ImmuneRegen BioSciences, Inc.
IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(R) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at http://www.immuneregen.com.
Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended June 30, 2007 and on Form 10-KSB for the twelve months ended December 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.
W. Jason Grimley
|SOURCE ImmuneRegen BioSciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved